Consumer demand for GLP-1 drugs like Ozempic and Wegovy has drawn a flood of new entrants. Yaccarino will have to find a way ...

Novo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes ...